mefloquine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreani, J; Boxberger, M; Delandre, O; Duflot, I; Fonta, I; Gendrot, M; Hutter, S; Jardot, P; La Scola, B; Le Bideau, M; Mosnier, J; Pradines, B; Rolland, C | 1 |
| Bojkova, D; Ciesek, S; Cinatl, J; Claussen, C; Ellinger, B; Geisslinger, G; Gribbon, P; Keminer, O; Kuzikov, M; Reinshagen, J; Westhaus, S; Wolf, M; Zaliani, A | 1 |
2 other study(ies) available for mefloquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Malaria; Malaria, Falciparum; Mefloquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells; Virus Replication | 2020 |
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Topics: Antiviral Agents; Benzamidines; Caco-2 Cells; Cetylpyridinium; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Esters; Guanidines; Humans; Lopinavir; Mefloquine; Papaverine; SARS-CoV-2 | 2021 |